Floatz logo

Ropidoxuridine

Stage IIIA Small Intestinal Cancer AJCC v7

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Stage IIIA Small Intestinal Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating
Vancomycin
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Dostarlimab
UNICANCER
Phase 2CCC
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
HUMAN ADENOVIRUS C SEROTYPE 5
Thomas Jefferson University
Phase 2CCC

View all 23 →

Same molecule, other indications

Ropidoxuridine is also rated in:

IDH-wildtype glioblastomaDormant
CC
Indicative ·
47 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CC
Indicative ·
41 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →